Authors: Sanchorawala, V Wright, DG Seldin, DC Dember, LM Finn, K Falk, RH Berk, J Quillen, K Skinner, M

Citation: V. Sanchorawala et al., An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis, BONE MAR TR, 28(7), 2001, pp. 637-642

Authors: Choufani, EB Sanchorawala, V Ernst, T Quillen, K Skinner, M Wright, DG Seldin, DC

Citation: Eb. Choufani et al., Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy, BLOOD, 97(6), 2001, pp. 1885-1887

Authors: Dember, LM Sanchorawala, V Seldin, DC Wright, DG LaValley, M Berk, JL Falk, RH Skinner, M

Citation: Lm. Dember et al., Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease, ANN INT MED, 134(9), 2001, pp. 746-753

Authors: Comenzo, RL Sanchorawala, V Fisher, C Akpek, G Farhat, M Cerda, S Berk, JL Dember, LM Falk, R Finn, K Skinner, M Vosburgh, E

Citation: Rl. Comenzo et al., Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis, BR J HAEM, 104(3), 1999, pp. 553-559